Highlights Gilead Sciences, Inc. Buenos Aires S.E.

Equities

GILD

ARBCOM4601C4

End-of-day quote Buenos Aires S.E. Other stock markets 03:30:00 01/07/2024 am IST			5-day change	1st Jan Change
24,177 ^ARS	+4.13%		+3.76%	+22.29%

01/07	HOOKIPA Pharma Reports First Patient Dosed in HIV Treatment Study	MT
01/07	HOOKIPA Pharma Inc. Announces First Person Dosed in Phase 1b Clinical Trial of HB-500 for the Treatment of HIV	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

HOOKIPA Pharma Inc. Announces First Person Dosed in Phase 1b Clinical Trial of HB-500 for the Treatment of HIV	02/07	CI
Gilead Sciences, Inc Announces New Data Support the Use of BICtegravir Tablet Regimen to Treat People with HIV and Individuals with HIV/HBV-Coinfection in Asia	27/06	CI
IDEAYA Biosciences Announces First-Patient-In for Phase 1 Clinical Trial Evaluating IDE397 and Trodelvy Combination in MTAP-Deletion Bladder Cancer	25/06	CI
Top Premarket Gainers	21/06	MT
Wall Street futures edge lower ahead of business survey data	21/06	RE
Equity Markets Close Mixed as Investors Weigh Economic Data	21/06	MT
Equity Markets Close Mixed After Macro Data	21/06	MT
Health Care Stocks Rise Behind Gilead -- Health Care Roundup	21/06	DJ
US Equities Markets Close Mixed Thursday as Markets Parse Latest Economic Data	21/06	MT
Sector Update: Health Care Stocks Higher Late Afternoon	21/06	MT
Sector Update: Health Care Stocks Mixed Thursday Afternoon	20/06	MT
Sliding Technology Stocks Push S&P 500, Nasdaq Composite Lower	20/06	MT
Sector Update: Health Care	20/06	MT
Gilead Sciences' Twice-Yearly Shot Prevents 100% of HIV Cases in Trial, Shares Jump	20/06	MT
Gilead Sciences' Lenacapavir Shows 100% Efficacy, Superiority to Truvada For HIV Prevention	20/06	MT
Gilead Sciences HIV Prevention Treatment Shows 100% Effectiveness in Phase 3 Trial	20/06	DJ
Gilead's long-acting HIV drug superior to daily pill Truvada in study	20/06	RE
Gilead Sciences, Inc. Announces Topline Results from an Interim Analysis of Its Pivotal, Phase 3 Purpose 1 Trial	20/06	CI
Health Care Slips as Gilead Rallies on Weight-Loss Plans - Health Care Roundup	15/06	DJ
EU regulator mandates label updates on CAR-T cancer therapies	14/06	RE

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Gilead Sciences, Inc. Buenos Aires S.E.

Equities

GILD

ARBCOM4601C4

Highlights

Filters